Advertisement

Picture Kentro Design Corporate and Web Design Berlin 600x60px
Organisation › Details

Galapagos N.V. (Euronext + Nasdaq: GLPG)

Galapagos (Euronext: GLPG; OTC: GLPYY) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action, with a pipeline comprising three Phase 2 programs, two Phase 1 trials, five pre-clinical studies, and 25 discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. In the field of inflammation, AbbVie and Galapagos signed a collaboration agreement for the development and commercialization of GLPG0634. GLPG0634 is an orally-available, selective inhibitor of JAK1 for the treatment of rheumatoid arthritis and potentially other inflammatory diseases, currently in Phase 2b studies in RA and in Phase 2 in Crohn’s disease. GLPG1205, a first-in-class inhibitor of GPR84, is currently being tested in a Phase 2 proof-of-concept trial in ulcerative colitis patients. GLPG1690 is a compound that targets pulmonary diseases and is currently in a Phase 1 trial. AbbVie and Galapagos also signed a collaboration agreement in cystic fibrosis to develop and commercialize molecules that address mutations in the CFTR gene. Potentiator GLPG1837 is currently in a Phase 1 trial, and corrector GLPG2222 is at the pre-clinical candidate stage. The Galapagos Group, including fee-for-service subsidiary Fidelta, has approximately 400 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, and Croatia. *

 

Period Start 1999-06-01 established_pre
  Group Galapagos (Group)
  Predecessor Galapagos Genomics N.V.
Product Industry genomics/genetics
Persons Person van de Stolpe, Onno (Galapagos 200501 CEO)
  Person 2 Filius, Bart (Galapagos 201412– CFO before Sanofi VP CFO at Sanofi Europe)
     
Region Region Mechelen
  Country Belgium
  Street Industriepark Mechelen Noord, Generaal De Wittelaan L11 A3
  City 2800 Mechelen
  Tel +32-15342900
    Address record changed: 2018-07-24
     
Basic data Employees E: 501 to 1,000 (2017-02-23)
  Currency EUR
  Annual sales 151,600,000 (revenues, consolidated (2016) 2016-12-31)
  Profit 54,000,000 (2016-12-31)
  Cash 980,900,000 (2016-12-31)
     
    * Document for �About Section�: Galapagos N.V.. (2/11/15). "Press Release: Galapagos Receives €1.6 Million IWT Grant for Hepatitis B Program". Mechelen.
     
   
Record changed: 2018-11-28

Advertisement

Picture [iito] – Putting Information into Context 600x60px

More documents for Galapagos (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Investors 600x60px




» top